The Calcimimetic AMG 073 as a Potential Treatment for Secondary Hyperparathyroidism of End-Stage Renal Disease

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The role of secondary hyperparathyroidism in anemia of end stage renal disease

Introduction: secondary hyperparathyroidism is listed among the possible reasons for intensifying the anemia and resistance to erythropoietin therapy in hemodialysis patients. Although its exact mechanism is not entirely clarified, but shift of bone marrow cells to adipocytes, bone marrow fibrosis and decreased calciteriol can be the causes. However, the role of secondary hyperparathyroidism in...

متن کامل

The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

Treatment with vitamin D sterols can lower plasma parathyroid hormone (PTH) in many patients with secondary hyperparathyroidism due to end-stage renal disease, but hypercalcemia, hyperphosphatemia, or both often develop during treatment. As such, alternative therapeutic approaches to managing excess PTH secretion are needed. Calcimimetic agents directly inhibit PTH secretion by activating the c...

متن کامل

Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article

Introduction End-stage renal disease (ESRD) is one of the most common life-threatening diseases with significant complication and poor outcomes (1-8). Possibly because of increasing prevalence of obesity, diabetes and hypertension, the number of ESRD patients increases each year and imposes a major social and economic burden on countries (9,10). Secondary hyperparathyroidism (SHPT) is a wellrec...

متن کامل

Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy

Standard therapy for secondary hyperparathyroidism (SHPT) includes dietary calcium supplementation, active vitamin D, and phosphate binders; however, these are often insufficient to allow patients to achieve their serum parathyroid hormone (PTH), calcium and calcium-phosphorus product (Ca × P) targets. Recent preclinical studies have demonstrated that treatment with type II calcimimetics that i...

متن کامل

Calcimimetic agents for the treatment of secondary hyperparathyroidism.

Calcimimetic agents function as allosteric activators of the calcium-sensing receptor (CaSR). In parathyroid tissue, they decrease the threshold for CaSR activation by extracellular calcium ions and diminish parathyroid hormone (PTH) secretion directly. Results from small clinical studies in hemodialysis patients with secondary hyperparathyroidism have shown that single oral doses of calcimimet...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of the American Society of Nephrology

سال: 2003

ISSN: 1046-6673,1533-3450

DOI: 10.1097/01.asn.0000050224.03126.ad